论文部分内容阅读
选择DPN患者60例,随机分为两组,对照组给予甲钴胺和前列地尔治疗,ALA组在对照组治疗的基础上再给予α-硫辛酸治疗,共5周,记录两组治疗前后的临床疗效、阳性症状VAS评分以及神经传导速度(NCV)的变化,并检测血清丙二醛(MDA)、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GSH-Px)活性变化。结果:治疗后5周两组的阳性症状VAS评分均较治疗前显著降低(P<0.05);治疗后5周,ALA组的VAS评分低于对照组(P<0.05);治疗后ALA组的正中神经、腓总神经感觉和运动传导速度与对照组比较差异有统计学意义(P<0.05);血清MDA含量明显降低,SOD和GSHPx活性则明显增加(P<0.05)。结论:ALA联合甲钴胺、前列地尔可明显改善DNP患者的临床症状,增加神经传导速度,其机制可能是通过抗氧化作用实现。
Sixty patients with DPN were selected and randomly divided into two groups. The control group was treated with mecobalamin and alprostadil. The ALA group was treated with α-lipoic acid on the basis of the control group, for 5 weeks. Before and after treatment (VAS score), and nerve conduction velocity (NCV) were measured. The serum levels of malondialdehyde (MDA), superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px) Activity changes. Results: The VAS scores of positive symptoms in both groups were significantly decreased 5 weeks after treatment (P <0.05). The VAS score of ALA group was lower than that of control group 5 weeks after treatment (P <0.05) The median nerve, peroneal nerve sensory and motor conduction velocity were significantly different from those in the control group (P <0.05). The content of MDA in serum and the activity of SOD and GSHPx in serum were significantly increased (P <0.05). Conclusion: ALA combined with mecobalamin and alprostadil can significantly improve the clinical symptoms and increase the nerve conduction velocity in patients with DNP. The mechanism may be through anti-oxidation.